Methoxyamine
- Generic Name
- Methoxyamine
- Drug Type
- Small Molecule
- Chemical Formula
- CH5NO
- CAS Number
- 67-62-9
- Unique Ingredient Identifier
- 9TZH4WY30J
- Indication
Investigated for use/treatment in cancer/tumors (unspecified).
Testing the Addition of an Anti-Cancer Drug, TRC102, to the Usual Chemotherapy Treatment (Pemetrexed, Cisplatin or Carboplatin) During Radiation Therapy for Stage III Non-Squamous Non-Small Cell Lung Cancer
- Conditions
- Stage III Lung Cancer AJCC v8Lung AdenocarcinomaLung Large Cell CarcinomaLung Non-Squamous Non-Small Cell Carcinoma
- Interventions
- Procedure: Computed TomographyProcedure: FDG-Positron Emission TomographyProcedure: Magnetic Resonance ImagingRadiation: Radiation Therapy
- First Posted Date
- 2022-01-20
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 42
- Registration Number
- NCT05198830
- Locations
- 🇺🇸
Keck Medicine of USC Buena Park, Buena Park, California, United States
🇺🇸City of Hope Comprehensive Cancer Center, Duarte, California, United States
🇺🇸City of Hope at Irvine Lennar, Irvine, California, United States
Methoxyamine Hydrochloride, Pemetrexed Disodium, Cisplatin, and Radiation Therapy in Treating Patients With Stage IIIA-IV Non-small Cell Lung Cancer
- Conditions
- Locally Advanced Lung Non-Squamous Non-Small Cell CarcinomaStage IV Lung Large Cell Carcinoma AJCC v7Stage III Lung Non-Small Cell Cancer AJCC v7Stage IIIA Lung Non-Small Cell Cancer AJCC v7Stage IIIB Lung Large Cell Carcinoma AJCC v7Stage IV Lung Adenocarcinoma AJCC v7Stage III Lung Adenocarcinoma AJCC v7Stage IV Lung Non-Small Cell Cancer AJCC v7Stage III Lung Large Cell Carcinoma AJCC v7Stage IIIA Lung Adenocarcinoma AJCC v7
- Interventions
- Radiation: 3-Dimensional Conformal Radiation TherapyRadiation: Intensity-Modulated Radiation Therapy
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2022-06-30
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 17
- Registration Number
- NCT02535325
- Locations
- 🇺🇸
Case Western Reserve University, Cleveland, Ohio, United States
Methoxyamine, Cisplatin, and Pemetrexed Disodium in Treating Patients With Advanced Solid Tumors or Mesothelioma That Cannot Be Removed by Surgery or Mesothelioma That Is Refractory to Pemetrexed Disodium and Cisplatin or Carboplatin
- Conditions
- Recurrent Pleural Malignant MesotheliomaUnresectable Solid NeoplasmRefractory Malignant Solid NeoplasmAdvanced Malignant Solid NeoplasmAdvanced Peritoneal Malignant MesotheliomaAdvanced Pleural Malignant MesotheliomaRecurrent Peritoneal Malignant Mesothelioma
- Interventions
- First Posted Date
- 2015-08-28
- Last Posted Date
- 2025-04-18
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT02535312
- Locations
- 🇺🇸
University of Pittsburgh Cancer Institute (UPCI), Pittsburgh, Pennsylvania, United States
🇺🇸University of Maryland/Greenebaum Cancer Center, Baltimore, Maryland, United States
🇺🇸Keck Medical Center of USC Pasadena, Pasadena, California, United States
Methoxyamine and Temozolomide in Treating Patients With Recurrent Glioblastoma
- Conditions
- Adult Brain Glioblastoma
- Interventions
- First Posted Date
- 2015-03-24
- Last Posted Date
- 2019-04-04
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 20
- Registration Number
- NCT02395692
- Locations
- 🇺🇸
Henry Ford West Bloomfield Hospital, West Bloomfield, Michigan, United States
🇺🇸Henry Ford Hospital, Detroit, Michigan, United States
🇺🇸Case Western Reserve University, Cleveland, Ohio, United States
TRC102 and Temozolomide for Relapsed Solid Tumors and Lymphomas
- Conditions
- Metastatic Colon CarcinomaSolid TumorsGranulosa Cell Ovarian CancerLymphomasNSCLC
- Interventions
- Diagnostic Test: CT scanOther: LomotilOther: ProchlorperazineOther: MetoclopramideOther: 5-HT3 antagonistOther: AprepitantProcedure: Biopsy
- First Posted Date
- 2013-05-10
- Last Posted Date
- 2024-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 93
- Registration Number
- NCT01851369
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies
- Conditions
- Adult Nasal Type Extranodal NK/T-cell LymphomaIntraocular LymphomaNodal Marginal Zone B-cell LymphomaPeripheral T-cell LymphomaRecurrent Adult Burkitt LymphomaRecurrent Adult Diffuse Large Cell LymphomaRecurrent Adult Diffuse Mixed Cell LymphomaRecurrent Adult Diffuse Small Cleaved Cell LymphomaRecurrent Adult Grade III Lymphomatoid GranulomatosisRecurrent Adult Hodgkin Lymphoma
- Interventions
- Other: laboratory biomarker analysisOther: pharmacological studyGenetic: western blottingOther: mass spectrometryGenetic: DNA analysis
- First Posted Date
- 2012-08-07
- Last Posted Date
- 2015-08-13
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 20
- Registration Number
- NCT01658319
- Locations
- 🇺🇸
Case Medical Center, University Hospitals Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Methoxyamine and Temozolomide in Treating Patients With Advanced Solid Tumors
- Conditions
- Unspecified Adult Solid Tumor, Protocol Specific
- Interventions
- First Posted Date
- 2009-05-04
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Case Comprehensive Cancer Center
- Target Recruit Count
- 66
- Registration Number
- NCT00892385
- Locations
- 🇺🇸
University Hospitals Cleveland Medical Center, Seidman Cancer Center, Case Comprehensive Cancer Center, Cleveland, Ohio, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.